Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement

Jan

09

Today In Oncology

ACS Guidelines for Cervical Cancer Self-Collected HPV Testing Now Included

Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL

Prostate Cancer: Novel PSMA-Targeted Radioligand Shows Reduced Salivary Gland Uptake in Preclinical Studies

CD123-Targeting ADC Shows Activity in AML and BPDCN

New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML

Advertisement

© 2026 HSP News Service, L.L.C.